Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial

Morihisa Hirota, Tooru Shimosegawa, Katsuya Kitamura, Kazunori Takeda, Yoshifumi Takeyama, Toshihiko Mayumi, Tetsuhide Ito, Mamoru Takenaka, Eisuke Iwasaki, Hirotaka Sawano, Etsuji Ishida, Shin Miura, Atsushi Masamune, Yousuke Nakai, Akira Mitoro, Hiroyuki Maguchi, Kenji Kimura, Tsuyoshi Sanuki, Tetsuya Ito, Hiroki HaradomeKazuto Kozaka, Toshifumi Gabata, Keisho Kataoka, Masahiko Hirota, Shuji Isaji, Ryoji Nakamura, Koki Yamagiwa, Chie Kayaba, Koji Ikeda

研究成果: Article査読

16 被引用数 (Scopus)

抄録

Background: Continuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis. Although this therapy is well known in Japan, its efficacy and safety remain unclear. Methods: This investigator-initiated and -driven, multicenter, open-label, randomized, controlled trial (UMIN000020868) enrolled 39 patients with predicted SAP and low enhancement of the pancreatic parenchyma on computed tomography (CT). Twenty patients were assigned to the CRAI group, while 19 served as controls and were administered NM at the same dose intravenously (IV group). The primary endpoint was the development of pancreatic necrosis as determined by CT on Day 14, judged by blinded central review. Results: There was no difference between the CRAI and IV groups regarding the percentages of participants who developed pancreatic necrosis (more than 1/3 of the pancreas: 25.0%, range 8.7–49.1% vs. 15.8%, range 3.4–39.6%, respectively, P = 0.694; more than 2/3 of the pancreas: 20%, range 5.7–43.7% vs. 5.3%, range 0.1–26.0%, respectively, P = 0.341). The early analgesic effect was evaluated based on 24-h cumulative fentanyl consumption and additional administration by intravenous patient-controlled analgesia. The results showed that the CRAI group used significantly less analgesic. There were two adverse events related to CRAI, namely bleeding and splenic infarction. Conclusions: CRAI with NM did not inhibit the development of pancreatic necrosis although early analgesic effect of CRAI was superior to that of IV. Less-invasive IV therapy can be considered a viable alternative to CRAI therapy.

本文言語English
ページ(範囲)342-352
ページ数11
ジャーナルJournal of gastroenterology
55
3
DOI
出版ステータスPublished - 2020 3 1

ASJC Scopus subject areas

  • 消化器病学

フィンガープリント

「Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル